1
|
Iwaki M, Kanemoto Y, Sawada T, Nojiri K, Kurokawa T, Tsutsumi R, Nagasawa K, Kato S. Differential gene regulation by a synthetic vitamin D receptor ligand and active vitamin D in human cells. PLoS One 2023; 18:e0295288. [PMID: 38091304 PMCID: PMC10718451 DOI: 10.1371/journal.pone.0295288] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2023] [Accepted: 11/16/2023] [Indexed: 12/18/2023] Open
Abstract
Vitamin D (VD) exerts a wide variety of biological functions including calcemic activity. VD nutritional status is closely associated with the onset and development of chronic diseases. To develop a VD analog with the desired VD activity but without calcemic activity, we screened synthetic VDR antagonists. We identified 1α,25-dihydroxyvitamin D3-26-23-lactams (DLAM)-2a-d (DLAM-2s) as nuclear vitamin D receptor (VDR) ligands in a competitive VDR binding assay for 1α,25(OH)2 vitamin D3 (1α,25(OH)2D3), and DLAM-2s showed an antagonistic effect on 1α,25(OH)2 D3-induced cell differentiation in HL60 cells. In a luciferase reporter assay in which human VDR was exogenously expressed in cultured COS-1 cells, DLAM-2s acted as transcriptional antagonists. Consistently, DLAM-2s had an antagonistic effect on the 1α,25(OH)2D3-induced expression of a known VD target gene [Cytochrome P450 24A1 (CYP24A1)], and VDR bound DLAM-2s was recruited to an endogenous VD response element in chromatin in human keratinocytes (HaCaT cells) endogenously expressing VDR. In an ATAC-seq assay, the effects of 1α,25(OH)2 D3 and DLAM-2b on chromatin reorganization were undetectable in HaCaT cells, while the effect of an androgen receptor (AR) antagonist (bicalutamide) was confirmed in prostate cancer cells (LNCaP) expressing endogenous AR. However, whole genome analysis using RNA-seq and ATAC (Assay for Transposase Accessible Chromatin)-seq revealed differential gene expression profiles regulated by DLAM-2b versus 1α,25(OH)2D3. The upregulated and downregulated genes only partially overlapped between cells treated with 1α,25(OH)2D3 and those treated with DLAM-2b. Thus, the present findings illustrate a novel VDR ligand with gene regulatory activity differing from that of 1α,25(OH)2D3.
Collapse
Affiliation(s)
- Miho Iwaki
- Graduate School of Technology, Tokyo University of Agriculture and Technology, Koganei, Tokyo, Japan
| | - Yoshiaki Kanemoto
- Graduate School of Life Science and Technology, Iryo Sosei University, Iino, Chuo-dai, Iwaki, Fukushima, Japan
- Research Institute of Innovative Medicine, Tokiwa Foundation, Iwaki, Fukushima, Japan
| | - Takahiro Sawada
- Graduate School of Life Science and Technology, Iryo Sosei University, Iino, Chuo-dai, Iwaki, Fukushima, Japan
- Research Institute of Innovative Medicine, Tokiwa Foundation, Iwaki, Fukushima, Japan
| | - Koki Nojiri
- Graduate School of Life Science and Technology, Iryo Sosei University, Iino, Chuo-dai, Iwaki, Fukushima, Japan
- Research Institute of Innovative Medicine, Tokiwa Foundation, Iwaki, Fukushima, Japan
| | - Tomohiro Kurokawa
- Research Institute of Innovative Medicine, Tokiwa Foundation, Iwaki, Fukushima, Japan
- School of Medicine, Fukushima Medical University, Fukushima, Japan
| | - Rino Tsutsumi
- Graduate School of Technology, Tokyo University of Agriculture and Technology, Koganei, Tokyo, Japan
| | - Kazuo Nagasawa
- Graduate School of Technology, Tokyo University of Agriculture and Technology, Koganei, Tokyo, Japan
| | - Shigeaki Kato
- Graduate School of Life Science and Technology, Iryo Sosei University, Iino, Chuo-dai, Iwaki, Fukushima, Japan
- Research Institute of Innovative Medicine, Tokiwa Foundation, Iwaki, Fukushima, Japan
- School of Medicine, Fukushima Medical University, Fukushima, Japan
| |
Collapse
|
3
|
A long non-coding RNA as a direct vitamin D target transcribed from the anti-sense strand of the human HSD17B2 locus. Biosci Rep 2022; 42:231267. [PMID: 35510872 PMCID: PMC9142830 DOI: 10.1042/bsr20220321] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2022] [Revised: 04/20/2022] [Accepted: 05/03/2022] [Indexed: 11/29/2022] Open
Abstract
Vitamin D (VD) exerts a wide variety of actions via gene regulation mediated by the nuclear vitamin D receptor (VDR) under physiological and pathological settings. However, the known target genes of VDR appear unlikely to account for all VD actions. We used in silico and transcriptomic approaches in human cell lines to search for non-coding RNAs transcriptionally regulated by VD directly. Four long non-coding RNAs (lncRNAs), but no microRNAs (miRNAs), were found, supported by the presence of consensus VDR-binding motifs in the coding regions. One of these lncRNAs (AS-HSD17β2) is transcribed from the antisense strand of the HSD17β2 locus, which is also a direct VD target. AS-HSD17β2 attenuated HSD17β2 expression. Thus, AS-HSD17β2 represents a direct lncRNA target of VD.
Collapse
|
4
|
Sawada T, Kanemoto Y, Amano R, Hayakawa A, Kurokawa T, Mori J, Kato S. Antagonistic action of a synthetic androgen ligand mediated by chromatin remodeling in a human prostate cancer cell line. Biochem Biophys Res Commun 2022; 612:110-118. [PMID: 35523048 DOI: 10.1016/j.bbrc.2022.04.109] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2022] [Accepted: 04/23/2022] [Indexed: 11/30/2022]
Abstract
The clinical use of androgen receptor (AR) antagonists has been successful in treating prostate cancer patients, inducing remission of androgen-dependent tumors. However, a couple of years after treatment, prostate tumors transition into an androgen-independent state with altered gene expression profiles, but the molecular basis is not understood. Since the AR antagonists trigger this transition, we assessed whether AR antagonists induce chromatin reorganization in an androgen-dependent prostate cancer cell line (LNCaP). Treatment of LNCaP cells with two clinically used AR antagonists (bicalutamide [Bic] and enzalutamide [Enz]) expectedly resulted in antagonistic effects on cell proliferation, AR transactivation, and dihydrotestosterone (DHT)-induced expression of AR target genes. Thus, the antagonists expectedly acted to antagonize the transactivation function of AR activated by androgen binding. By ChIP-qPCR assay, AR bound to Bic, but not Enz, was recruited to an endogenous consensus AR-binding site within the kallikrein-related peptidase 3 gene promoter after treatment with Bic, similar to the effect of DHT. By ATAC-seq analysis of the cells after long-term treatment for 5 days, Bic and dihydrotestosterone DHT induced different chromatin reorganization patterns and gene expression profiles, suggesting that Bic exhibited a distinct action from that by DHT. Thus, these results suggest that the action of a known AR antagonist is mediated by chromatin reorganization in a prostate cancer cell line.
Collapse
Affiliation(s)
- Takahiro Sawada
- Graduate School of Life Science and Engineering, Iryo Sosei University, Iino, Chuo-dai, Iwaki, Fukushima, 9708551, Japan; Research Institute of Innovative Medicine, Tokiwa Foundation, Iwaki, Fukushima, Japan
| | - Yoshiaki Kanemoto
- Graduate School of Life Science and Engineering, Iryo Sosei University, Iino, Chuo-dai, Iwaki, Fukushima, 9708551, Japan; Research Institute of Innovative Medicine, Tokiwa Foundation, Iwaki, Fukushima, Japan
| | - Rei Amano
- Research Institute of Innovative Medicine, Tokiwa Foundation, Iwaki, Fukushima, Japan
| | - Akira Hayakawa
- Graduate School of Life Science and Engineering, Iryo Sosei University, Iino, Chuo-dai, Iwaki, Fukushima, 9708551, Japan; Research Institute of Innovative Medicine, Tokiwa Foundation, Iwaki, Fukushima, Japan
| | - Tomohiro Kurokawa
- Graduate School of Life Science and Engineering, Iryo Sosei University, Iino, Chuo-dai, Iwaki, Fukushima, 9708551, Japan; Research Institute of Innovative Medicine, Tokiwa Foundation, Iwaki, Fukushima, Japan; School of Medicine, Fukushima Medical University, Fukushima, Fukushima, 960-1295, Japan
| | - Jinichi Mori
- Graduate School of Life Science and Engineering, Iryo Sosei University, Iino, Chuo-dai, Iwaki, Fukushima, 9708551, Japan; Research Institute of Innovative Medicine, Tokiwa Foundation, Iwaki, Fukushima, Japan; Department of Hematology, Jyoban Hospital, Tokiwa Foundation, Iwaki, Fukushima, Japan; School of Medicine, Fukushima Medical University, Fukushima, Fukushima, 960-1295, Japan
| | - Shigeaki Kato
- Graduate School of Life Science and Engineering, Iryo Sosei University, Iino, Chuo-dai, Iwaki, Fukushima, 9708551, Japan; Research Institute of Innovative Medicine, Tokiwa Foundation, Iwaki, Fukushima, Japan; School of Medicine, Fukushima Medical University, Fukushima, Fukushima, 960-1295, Japan.
| |
Collapse
|